Clinical trial

Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma

NCT05736991

Study summary

ClinicalTrials.gov

Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma

Design: OBSERVATIONAL · Status: UNKNOWN · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DIAGNOSTIC_TEST · Unmapped registry intervention PET/CT-based Radiomics Signature Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeOBSERVATIONAL

Start date2022-11-01

PhaseN/A

Conditions

Lung Adenocarcinomaverified · MONDO: lung adenocarcinoma

Radiomicsunresolved

Grading Systemunresolved

Interventions

PET/CT-based Radiomics SignatureDIAGNOSTIC_TEST

Sponsors & collaborators

Shanghai Pulmonary Hospital, Shanghai, Chinalead sponsor

Ningbo No.2 Hospitalcollaborator

Zunyi Medical Collegecollaborator

The First Affiliated Hospital of Nanchang Universitycollaborator

Mapped research locations

NanchangJiangxi, China1 NingboZhejiang, China1 ZunyiGuizhou, China1 YangpuShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05736991 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.